AMOA
MCID: ANP008
MIFTS: 31

Anaplastic Oligoastrocytoma (AMOA)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Anaplastic Oligoastrocytoma

MalaCards integrated aliases for Anaplastic Oligoastrocytoma:

Name: Anaplastic Oligoastrocytoma 53 59 17 72
Amoa 59

Characteristics:

Orphanet epidemiological data:

59
anaplastic oligoastrocytoma
Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 73 C0431108
Orphanet 59 ORPHA251663
UMLS 72 C0431108

Summaries for Anaplastic Oligoastrocytoma

NIH Rare Diseases : 53 Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma. An oligoastrocytoma is described as anaplastic when the tumor grows quickly and the cancer cells within the tumor have the potential to spread into surrounding brain tissue or to more distant parts of the body. Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50. The exact cause of this condition is unknown.

MalaCards based summary : Anaplastic Oligoastrocytoma, also known as amoa, is related to oligoastrocytoma and oligodendroglioma. An important gene associated with Anaplastic Oligoastrocytoma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2). The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and bone.

Related Diseases for Anaplastic Oligoastrocytoma

Diseases related to Anaplastic Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 31)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 10.8
2 oligodendroglioma 10.5
3 astrocytoma 10.4
4 anaplastic oligodendroglioma 10.4
5 glioma 10.4
6 glial tumor 10.4
7 glioblastoma multiforme 10.4
8 grade iii astrocytoma 10.4
9 glioblastoma 10.4
10 mixed glioma 10.2
11 3-methylcrotonyl-coa carboxylase 1 deficiency 10.2
12 anoxia 10.2
13 supernumerary breasts 10.2
14 medulloblastoma 10.1
15 mismatch repair cancer syndrome 10.1
16 leukemia, acute myeloid 10.1
17 meningioma, radiation-induced 10.1
18 meningioma, familial 10.1
19 leukemia, acute lymphoblastic 10.1
20 cerebellar medulloblastoma 10.1
21 cysticercosis 10.1
22 lymphocytic leukemia 10.1
23 spinal meningioma 10.1
24 secretory meningioma 10.1
25 lymphoplasmacyte-rich meningioma 10.1
26 paraplegia 10.1
27 childhood leukemia 10.1
28 myeloid leukemia 10.1
29 opsoclonus-myoclonus syndrome 10.1
30 spastic paraparesis 10.1
31 myoclonus 10.1

Graphical network of the top 20 diseases related to Anaplastic Oligoastrocytoma:



Diseases related to Anaplastic Oligoastrocytoma

Symptoms & Phenotypes for Anaplastic Oligoastrocytoma

Drugs & Therapeutics for Anaplastic Oligoastrocytoma

Drugs for Anaplastic Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
3
tannic acid Approved Phase 3 1401-55-4
4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
5
Histamine Approved, Investigational Phase 3 51-45-6 774
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7 Anesthetics, Local Phase 3
8 Central Nervous System Depressants Phase 3
9 Anesthetics Phase 3
10 Peripheral Nervous System Agents Phase 3
11 Interferon-alpha Phase 3
12 interferons Phase 3
13 Antiviral Agents Phase 3
14 Interferon alpha-2 Phase 3
15 Dermatologic Agents Phase 3
16 Gastrointestinal Agents Phase 3
17 Neurotransmitter Agents Phase 3
18 Anti-Allergic Agents Phase 3
19 Serotonin Antagonists Phase 3
20 Histamine H1 Antagonists Phase 3
21 Histamine Antagonists Phase 3
22 Serotonin Agents Phase 3
23
Histamine Phosphate Phase 3 51-74-1 65513
24 Antipruritics Phase 3
25
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
26
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
27
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
28
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
29
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
30
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
31
Acetaminophen Approved Phase 2 103-90-2 1983
32
Promethazine Approved, Investigational Phase 2 60-87-7 4927
33
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
35
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
36
Iodine Approved, Investigational Phase 2 7553-56-2 807
37
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
38
Trioxsalen Approved Phase 2 3902-71-4 5585
39
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
40 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
41 Keratolytic Agents Phase 1, Phase 2
42 Tubulin Modulators Phase 1, Phase 2
43 Podophyllotoxin Phase 1, Phase 2 518-28-5
44 Antimitotic Agents Phase 1, Phase 2
45 Immunosuppressive Agents Phase 2
46 Natriuretic Agents Phase 2
47 diuretics Phase 2
48 Anti-Infective Agents Phase 2
49 Antineoplastic Agents, Immunological Phase 2
50 Micronutrients Phase 2

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
2 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
3 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
4 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
6 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
7 Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed NCT00859222 Phase 1, Phase 2 LBH589;bevacizumab
8 A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
9 Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
10 Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
11 Phase I Trial of TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Recruiting NCT02942264 Phase 1, Phase 2 TG02;TMZ
12 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
13 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
14 A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults Terminated NCT01966809 Phase 2 Photofrin photodynamic therapy.
15 Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
16 Phase I/II Trial of Cabazitaxel in Adult Patients With Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
17 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
18 A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma Completed NCT01156584 Phase 1 Toca FC
19 A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC Completed NCT01985256 Phase 1 Toca FC
20 A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC Completed NCT01470794 Phase 1 Toca FC
21 Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation
22 A Phase I Study of SU011248 Plus Irinotecan in the Treatment of Patients With Malignant Glioma Completed NCT00611728 Phase 1 SU011248 & Irinotecan
23 A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas Completed NCT00612651 Phase 1 Temodar and SCH 66336
24 A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas Completed NCT01273090 Phase 1 imetelstat sodium
25 Phase Ib Study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children Recruiting NCT03043391 Phase 1
26 Phase I Trial of Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme Terminated NCT00671801 Phase 1 Irinotecan;Lenalidomide
27 Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ? Unknown status NCT03068520
28 Diagnostic And Prognostic Markers In High-Grade Glioma Completed NCT01004887
29 Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients and Setting up a Large-scale, Prospective Database for Glioma Patients Treated in UZ Leuven Recruiting NCT03849430

Search NIH Clinical Center for Anaplastic Oligoastrocytoma

Genetic Tests for Anaplastic Oligoastrocytoma

Anatomical Context for Anaplastic Oligoastrocytoma

MalaCards organs/tissues related to Anaplastic Oligoastrocytoma:

41
Brain, Eye, Bone, Spinal Cord, Colon, Testes, Bone Marrow

Publications for Anaplastic Oligoastrocytoma

Articles related to Anaplastic Oligoastrocytoma:

(show top 50) (show all 1275)
# Title Authors PMID Year
1
Genetic associations as indices for assessing nitrogen transformation processes in co-composting of cattle manure and rice straw. 38
31344636 2019
2
Nonylphenol causes shifts in microbial communities and nitrogen mineralization in soil microcosms. 38
31212188 2019
3
Effects of combined biochar and organic fertilizer on nitrous oxide fluxes and the related nitrifier and denitrifier communities in a saline-alkali soil. 38
31176819 2019
4
Aged biochar stimulated ammonia-oxidizing archaea and bacteria-derived N2O and NO production in an acidic vegetable soil. 38
31212151 2019
5
Isolation and identification of a salt-tolerant aerobic denitrifying bacterial strain and its application to saline wastewater treatment in constructed wetlands. 38
31301568 2019
6
Effects of allochthonous dissolved organic matter input on microbial composition and nitrogen-cycling genes at two contrasting estuarine sites. 38
31397876 2019
7
Simultaneous nitrification and denitrification by a novel isolated Pseudomonas sp. JQ-H3 using polycaprolactone as carbon source. 38
31128537 2019
8
An RNA-based quantitative and compositional study of ammonium-oxidizing bacteria and archaea in Lake Taihu, a eutrophic freshwater lake. 38
31314099 2019
9
Effects of earthworms on nitrogen transformation and the correspond genes (amoA and nirS) in vermicomposting of sewage sludge and rice straw. 38
31096104 2019
10
Nitrous oxide emissions associated with ammonia-oxidizing bacteria abundance in fields of switchgrass with and without intercropped alfalfa. 38
31430046 2019
11
Nitrate addition promotes the nitrogen cycling processes under the co-contaminated tetrabromobisphenol A and copper condition in river sediment. 38
31108299 2019
12
Separate and joint eco-toxicological effects of sulfadimidine and copper on soil microbial biomasses and ammoxidation microorganisms abundances. 38
31055070 2019
13
Effects of Exogenous N-Acyl-Homoserine Lactone as Signal Molecule on Nitrosomonas Europaea under ZnO Nanoparticle Stress. 38
31434344 2019
14
The negative impact of cadmium on nitrogen transformation processes in a paddy soil is greater under non-flooding than flooding conditions. 38
31154147 2019
15
Reduction of N2O emission by biochar and/or 3,4-dimethylpyrazole phosphate (DMPP) is closely linked to soil ammonia oxidizing bacteria and nosZI-N2O reducer populations. 38
31398644 2019
16
Cometabolic biodegradation of cephalexin by enriched nitrifying sludge: Process characteristics, gene expression and product biotoxicity. 38
30959294 2019
17
Dynamics and underlying mechanisms of N2O and NO emissions in response to a transient land-use conversion of Masson pine forest to tea field. 38
31374503 2019
18
The N-fixing legume Periandra mediterranea constrains the invasion of an exotic grass (Melinis minutiflora P. Beauv) by altering soil N cycling. 38
31363104 2019
19
Insights into functional microbial succession during nitrogen transformation in an ectopic fermentation system. 38
30952054 2019
20
Long-term N fertilization imbalances potential N acquisition and transformations by soil microbes. 38
31325856 2019
21
Abundance and community composition of comammox bacteria in different ecosystems by a universal primer set. 38
31319252 2019
22
Genomic adaptation to eutrophication of ammonia-oxidizing archaea in the Pearl River estuary. 38
30924222 2019
23
Fast start-up strategies of MBBR for mariculture wastewater treatment. 38
31325791 2019
24
Depth distributions of nitrite reductase (nirK) gene variants reveal spatial dynamics of thaumarchaeal ecotype populations in coastal Monterey Bay. 38
31330081 2019
25
Peat substrate amended with chitin modulates the N-cycle, siderophore and chitinase responses in the lettuce rhizobiome. 38
31289280 2019
26
Linking changes in snow cover with microbial nitrogen cycling functional gene abundance and expression in agricultural soil. 38
31167230 2019
27
Changes in nitrogen functional genes in soil profiles of grassland under long-term grazing prohibition in a semiarid area. 38
30986685 2019
28
Effect of soil types and ammonia concentrations on the contribution of ammonia-oxidizing bacteria to CH4 oxidation. 38
31023154 2019
29
Variable responses of nitrification and denitrification in a paddy soil to long-term biochar amendment and short-term biochar addition. 38
31229717 2019
30
Short term changes in the abundance of nitrifying microorganisms in a soil-plant system simultaneously exposed to copper nanoparticles and atrazine. 38
31018422 2019
31
The response of nitrogen removal and related bacteria within constructed wetlands after long-term treating wastewater containing environmental concentrations of silver nanoparticles. 38
30833250 2019
32
Adaptive responses of comammox Nitrospira and canonical ammonia oxidizers to long-term fertilizations: Implications for the relative contributions of different ammonia oxidizers to soil nitrogen cycling. 38
30852199 2019
33
Spatial and Seasonal Variations in the Abundance of Nitrogen-Transforming Genes and the Microbial Community Structure in Freshwater Lakes with Different Trophic Statuses. 38
31261730 2019
34
Comparison of the microbiomes of two drinking water distribution systems-with and without residual chloramine disinfection. 38
31174608 2019
35
Plant-driven niche differentiation of ammonia-oxidizing bacteria and archaea in global drylands. 38
31249390 2019
36
Comammox Nitrospira are the dominant ammonia oxidizers in a mainstream low dissolved oxygen nitrification reactor. 38
30974288 2019
37
Strategy of rapid start-up and the mechanism of de-nitrogen in landfill bioreactor. 38
30928790 2019
38
Responses of Active Ammonia-oxidizers and Nitrification Activity in Eutrophic Lake Sediments to Nitrogen and Temperature. 38
31253684 2019
39
Functional dominance and community compositions of ammonia-oxidizing archaea in extremely acidic soils of natural forests. 38
30923872 2019
40
Vertical distribution of particle-associated and free-living ammonia-oxidizing archaea in Suruga Bay, a deep coastal embayment of Japan. 38
31147749 2019
41
Particle-attached microorganism oxidation of ammonia in a hypereutrophic urban river. 38
30900742 2019
42
Effect of aeration and hydraulic loading rate on nitrogen removal by subsurface infiltration systems. 38
30784134 2019
43
Mudflat reclamation causes changes of gene abundance in nitrogen cycle under long-term rice cultivation. 38
30900740 2019
44
Metagenomic analysis of nitrogen-cycling genes in upper Mississippi river sediment with mussel assemblages. 38
30270525 2019
45
Successive phytoextraction alters ammonia oxidation and associated microbial communities in heavy metal contaminated agricultural soils. 38
30763842 2019
46
Nitrification inhibitors effectively target N2 O-producing Nitrosospira spp. in tropical soil. 38
30735001 2019
47
Reducing ammonia volatilization from paddy field with rice straw derived biochar. 38
30640118 2019
48
Long- and short-chain AHLs affect AOA and AOB microbial community composition and ammonia oxidation rate in activated sludge. 38
30665656 2019
49
Historical Nitrogen Deposition and Straw Addition Facilitate the Resistance of Soil Multifunctionality to Drying-Wetting Cycles. 38
30737352 2019
50
Effects of Oenanthe javanica on Nitrogen Removal in Free-Water Surface Constructed Wetlands under Low-Temperature Conditions. 38
31010264 2019

Variations for Anaplastic Oligoastrocytoma

Expression for Anaplastic Oligoastrocytoma

Search GEO for disease gene expression data for Anaplastic Oligoastrocytoma.

Pathways for Anaplastic Oligoastrocytoma

GO Terms for Anaplastic Oligoastrocytoma

Sources for Anaplastic Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....